Edward Marks's questions to Stoke Therapeutics Inc (STOK) leadership • Q2 2025
Question
Edward Marks, on behalf of Joseph Stringer from Needham & Company, asked about the timing of the North American commercial build-out and sales force size, as well as details on the ADOA Phase 1 trial, including genetic screening requirements and data cadence.
Answer
Chief Patient Officer Jason Hoitt outlined a slow, deliberate commercial build, anticipating a peak of around 20 salespeople with a focus on patient support. Interim CEO Ian Smith added the strategy is centered on education and access, not a traditional sales model. For ADOA, he described the Phase 1 as a safety-focused, dose-escalating study where updates will be provided if meaningful efficacy data emerges. CMO Barry Ticho noted that OPA1 genetic testing is available but underutilized, necessitating an education campaign.